The early promise of Cabaletta Bio's therapy in treating autoimmune diseases is a positive development, potentially boosting investor confidence. The company's financial stability for the next 5-6 quarters is reassuring. However, the aggressive nature of the therapy and competition are significant risks that could impact future performance.